Company News

Yongchang Qiu, PhD

Dr. Qiu is a highly experienced drug hunter and developer with 20+ year experiences in drug discovery and development at pharmaceutical and biotechnology companies as well as venture capital investment. He has contributed directly to many successful IND and BLA/NDA filings for a variety of drug modalities, including small molecules, biologics and gene therapies.

Prior to founding Lysoway therapeutics in October 2022, Dr. Qiu was the vice president of preclinical development at Cydan, a rare disease venture/accelerator company which specializes in identifying and investing in rare disease drug assets. Before joining Cydan, Dr. Qiu was head of DMPK and bioanalytical science at Tesaro and a senior director and global head of bioanalytical and biomarker development at Shire, leading a team of 40+ scientists including 25 PhDs and 6 directors. He was responsible for design, development, and implementation of biomarker strategy, immunogenicity risk assessment, as well as safety and diagnostic testing strategies to support 70+ development programs within Shire. Prior to Shire, Dr. Qiu was a director in translational research at Genzyme focusing on preclinical pharmacology and biomarker development for multiple rare disease programs. Dr. Qiu began his career in discovery research at Wyeth in 1998, eventually serving as head of protein chemistry and proteomics.

Dr. Qiu earned his PhD in Pharmaceutical Chemistry and Biopharmaceutical Sciences at University of California at San Francisco, an MS in Organic Chemistry at New York University and a BS in Chemistry from University of Science and Technology of China. Dr. Qiu has authored 70+ peer-reviewed research articles and original patents covering a variety of therapeutics areas.

Xiang Yang Yu, PhD

Dr. Xiang Yang Yu has successful experience in drug discovery, pre-clinical & clinical studies and global regulatory filing strategies with a broad understanding of new drug development trends. Dr. Yu is an expert on MedChem Compound Design based on SAR, preclinical development & CMC.

Dr. Yu has been head of chemistry at Lysoway leading drug discovery programs since October 2020. Dr. Yu was a program manager at Accellient Partners with responsibilities for API and drug product CMC manufacture as well as for regulatory filings. She was also involved in multiple clinical trials from Phase I to Phase III in multiple therapeutic areas. Prior to that, she was a principal investigator at Ironwood Pharmaceuticals where she successfully led drug discovery and development programs in multiple therapeutic areas as well as efficiently and strategically managed external drug discovery and development collaborations in the US, Europe and Asia. Prior to joining Ironwood, Dr. Yu was director of medicinal chemistry at Epix Pharmaceuticals leading successful drug discovery programs. She was the chemistry project leader for S1P program licensed to Amgen for highly potent, selective and orally active agents for autoimmune diseases leading to $20 million upfront payment and $307 million milestone payment in a record 9 months. Dr. Yu was also a chemistry project leader for a GSK collaborative discovery program which resulted in $5.5 million upfront payment in 7 months. Before joining Epix, she led multiple anti-infectious programs at Activbiotics and Cubist Pharmaceuticals.

She obtained her MS and PhD degree in Organic Chemistry from Florida State University and received her undergraduate degree from East China University of Science & Technology in Shanghai. Dr. Yu is a board director and president of the Chinese American BioMedical Association (CABA) since 2014 (a 501(C)(3) not-for-profit professional organization. She was the president of CABA – (2013-2014). She is a co-chair in MassBio Forum at MassBio and a BayHelix member.

Soheil Aghamohammadzadeh, PhD

Soheil joins Lysoway with more than 10 years of experience in small molecule drug discovery targeting multiple therapeutic areas including neuroscience, respiratory, and dermatology. He has experience working across large pharmaceutical companies like Pfizer and small biotech companies like Proteostasis Therapeutics and Eloxx Pharmaceuticals. He comes with the expertise of transitioning 4 molecules from early discovery to clinic.

At Eloxx Pharmaceuticals, Soheil was a project lead for two rare disease programs including cystic fibrosis (CF) and recessive dystrophic epidermolysis bullosa (RDEB). At Eloxx, he was instrumental in writing and receiving a $2.6M grant from the CF foundation to develop therapies for CF patients. Prior to Eloxx, he was a pharmacology lead at Proteostasis Therapeutics where he managed a team that generated IND enabling data packages for 3 clinical candidates.

Soheil holds a PhD in Cell Biology from Sheffield University (UK) and completed his postdoctoral fellowship at Pfizer Neuroscience Research Unit. His focus at Pfizer was on the dysfunction of the protein degradation pathway in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Soheil is passionate about drug discovery, with the aim to provide disease modifying therapies for patients with unmet medical need.

Junsheng Yang, PhD

Junsheng joins Lysoway with more than 15 years of research experience in autophagy, lysosome biology, Huntington disease and the molecular biology of aging. He has experience as an PI in Zhejiang University of Technology (China) where his research on HD was supported by NSFC and Zhejiang NSF grants. He has published more than 20 peer-reviewed articles on the molecular mechanisms of HD, the functions of lysosomal ion channels and the genetics of aging. Junsheng also has more than 5 years experience as a consultant for drug discovery research focusing on diseases manifesting lysosomal storage.

Junsheng holds a PhD in Molecular Biology from the University of Southern California (USA) and completed his postdoctoral fellowship at the University of Gothenburg (Sweden). Junsheng is especially interested in translational research, aiming to apply findings in fundamental cell biology and disease mechanisms to potential new drug discoveries.